SMS Pharmaceuticals Limited is an India-based pharmaceutical manufacturing company. The Company is engaged in the business of manufacturing active pharma ingredients and their intermediates. Its product categories include anti-ulcer, anti-inflammatory, anti-migraine, ant-diabetic, anti-coagulant, anti-viral, anti-retroviral, anti-psychotic, and others. The Company products include ranitidine, famotidine, pantoprazole sodium, itraconazole, lanoconazole, luliconazole, ibuprofen, Dex ibuprofen, fenoprofen calcium, sumatriptan, almotriptan, zolmitriptan, rizatriptan, Ele triptan, vildagliptin, sitagliptin, rosiglitazone, empagliflozin, dapagliflozin, tenofovir, dolutegravir, raltegravir, lamivudine, efavirenz, apixaban, rivaroxaban, levetiracetam, perampanel, lamotrigine, penciclovir, valaciclovir, and others. The Company has manufacturing facilities at Bachupally, Hyderabad, Telangana and also at Kandivalasa Village, Poosapatirega Mandal, Vijayanagaram District, Andhra Pradesh.As of 25 May 2026, SMS Pharmaceuticals share price is ₹369.15. The stock opened at ₹385.00, compared to its previous close of ₹381.45. During today's trading session, SMS Pharmaceuticals share price moved in the range of ₹361.70 to ₹389.40, with an average price of ₹375.55 for the day. Looking at its last 52-week, the stock has touched a low of ₹361.70 and a high of ₹389.40. On the performance front, SMS Pharmaceuticals share price has increased by 34.95% over the last six months and is up 40.82% on a year-on-year basis.
The market capitalization of SMS Pharmaceuticals is ₹3,570 Crs, with a P/E ratio of 35.0 and a dividend yield of 0.10%.